SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
نویسندگان
چکیده
Diabetic kidney disease (DKD) is the most common cause of end stage renal disease. The comprehensive management of DKD depends on combined target-therapies for hyperglycemia, hypertension, albuminuria, and hyperlipaemia, etc. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, the most recently developed oral hypoglycemic agents acted on renal proximal tubules, suppress glucose reabsorption and increase urinary glucose excretion. Besides improvements in glycemic control, they presented excellent performances in direct renoprotective effects and the cardiovascular (CV) safety by decreasing albuminuria and the independent CV risk factors such as body weight and blood pressure, etc. Simultaneous use of SGLT-2 inhibitors and renin–angiotensin–aldosterone system (RAAS) blockers are novel strategies to slow the progression of DKD via reducing inflammatory and fibrotic markers induced by hyperglycaemia more than either drug alone. The available population and animal based studies have described SGLT2 inhibitors plus RAAS blockers. The present review was to systematically review the potential renal benefits of SGLT2 inhibitors combined with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, mineralocorticoid receptor antagonists, and especially the angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.
منابع مشابه
Safety of sodium-glucose co-transporter 2 inhibitors during Ramadan fasting: Evidence, perceptions and guidelines
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new glucose-lowering therapy for T2DM with documented benefits on blood glucose, hypertension, weight reduction and long term cardiovascular benefit. They have an inherent osmotic diuretic effect and lead to some volume loss and possible dehydration. There is some concern about the safety of using SGLT2 inhibitors in Muslim type 2 diabete...
متن کاملCorrection to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Following publication of the original article [1] the authors reported that the first affiliation ("Medical Center of the Graduate School, Nanchang University, China") had been added in error, and that the correct author information is as given in this erratum.
متن کاملPreventing diabetic renal disease: the potential reno-protective effects of SGLT2 inhibitors
Diabetic renal disease is associated with increased cardiovascular risk and is one of the leading causes of end-stage renal disease worldwide. A combination of hyperglycaemia and hypertension drives the development and progression of diabetic renal disease, with glomerular hyperfiltration being an early manifestation of the disease process. Sodiumglucose linked transporter 2 (SGLT2) inhibitors ...
متن کاملSodium Glucose Transport 2 (SGLT2) Inhibition Decreases Glomerular Hyperfiltration: Is There a Role for SGLT2 Inhibitors in Diabetic Kidney Disease? Running title: Stanton; SGLT2 Inhibition and Diabetic kidney Disease
متن کامل
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors1
Background: Sodium glucose cotransporter-2 (SGLT2) inhibitors are recommended by the American Diabetes Association (ADA) for the treatment of type 2 diabetes as one of six second-line therapy options after initial therapy with metformin. In addition, they have been studied in combination with insulin as a potential option for treating patients with type 1 diabetes. These medications act by inhi...
متن کامل